If You Invested $1000 In This Stock 5 Years Ago, Here’s How Much You Would Have Today
Intellia Therapeutics (NASDAQ:NTLA) has outperformed the market over the past 5 years by 32.37% on an annualized basis.
What 4 Analyst Ratings Have To Say About Intellia Therapeutics
Analysts have provided the following ratings for Intellia Therapeutics (NASDAQ:NTLA) within the last quarter:
Intellia Therapeutics And Kyverna Therapeutics Announce Collaboration To Develop Next-Generation Allogeneic T-Cell Therapy For Autoimmune Diseases
— Intellia grants Kyverna exclusive rights to its differentiated allogeneic cell engineering platform for the development of KYV-201, a next-generation CD19 CAR T-cell therapy to treat autoimmune diseases
Cathie Wood’s ARK Invest Posts Fund Purchases For Monday, Dec. 13, 2021: SYSS, NTLA, DNA, PD, BLI, CRSP, MTLS, NVTA, VUZI, BLDE, ROKU, COIN, EDR, ONEM, SDGR, ACCD, SLGC, MASS, QSI, PSNL, PATH, TOST, HOOD, SE, NU, KTOS, AVAV
STRATASYS LTD (SSYS) - 78600
INTELLIA THERAPEUTICS INC (NTLA) - 16800
GINKGO BIOWORKS HOLDINGS INC (DNA) - 130745
PAGERDUTY INC (PD) - 24394
BERKELEY LIGHTS INC (BLI) - 29549
CRISPR THERAPEUTICS AG (CRSP) -
Intellia Therapeutics Announces First Patient Dosed In Phase 1/2 Clinical Trial Of NTLA-2002 For The Treatment Of Hereditary Angioedema
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today announced
54 Biggest Movers From Yesterday
Gainers
Siyata Mobile Inc. (NASDAQ: SYTA) shares jumped 66.7% to close at $4.60 on Tuesday. Siyata Mobile received $1.3 million purchase order for SD7 ruggedized devices and accessories.
36 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
Siyata Mobile Inc. (NASDAQ: SYTA) shares climbed 123.2% to $6.16. Siyata Mobile received $1.3 million purchase order for SD7 ruggedized devices and accessories.
Cathie Wood’s ARK Invest Posts Fund Purchases For Monday, Nov. 15, 2021: NTLA, TWOU, VCYT, BEAM, MTLS, PRLB, TSP, ACHR, VLD, SPLK, DIS, BFLY, SGFY, ONEM, ALLO, VERV, QSI, HOOD, DKNG, TWLO, TOST, PAG, GRMN, DDD, MKFG
Intellia Therapeutics (NTLA)
2U (TWOU)
Veracyte (VCYT)
Beam Therapeutics (BEAM)
Materialise (MTLS)
Proto Labs (PRLB)
TuSimple Holdings (TSP)
Archer Aviation (ACHR)
Velo3d (VLD)
Splunk (SPLK)
The Walt Disney
Intellia Therapeutics To Highlight Ex Vivo Genome Editing, CRISPR/Cas9 Manufacturing Advances At 2021 American Society Of Hematology Annual Meeting
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today